Specificity of the FTA-ABS and TPHA tests during pregnancy.

Manikowska-Lesińska, W; Linda, Bohdan; Zájac, W

doi:10.1136/sti.54.5.295

Cited by 6 publications

(4 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some reports have shown higher rates (22), but the rate depends on the population studied. If the population includes patients with other treponemal diseases (3), autoimmune disorders such as systemic lupus erythematosus (5,17,25), drug addiction (12,20,25), genital herpes (20,30), or leprosy (20, 25), or if there are elderly (9,20,25) or pregnant (2,18,20,26) patients, the likelihood of a false-positive cardiolipin test result increases. If a screening method with higher specificity were available, false-positive results would be minimized.…”

mentioning

confidence: 99%

Evaluation of a Treponema pallidum enzyme immunoassay as a screening test for syphilis

Hooper

Malloy

Passen

1994

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

The CAPTIA Syphilis-G enzyme immunoassay for the detection of antibodies to Treponema paUlidum was evaluated as a screening test for syphilis in comparison with the standard rapid plasma reagin (RPR) test. One thousand samples were tested, and the standard fluorescent treponemal antibody absorption test and the standard microhemmaglutination test were used to confirm the presence of treponemal antibodies. Diagnosis of syphilis was based on traditional standard serology results. Clinical data used in the diagnosis of patients whose samples yielded conflicting results were provided by physicians. Initially, 7 patients whose samples were reactive in the RPR test and 14 patients whose samples yielded positive or equivocal results in the CAPTIA Syphilis-G test were diagnosed as not being infected. After discrepancies due to technical problems were reconciled, samples from six patients remained reactive in the RPR test and that from one patient remained positive in the CAPTIA Syphilis-G test. In addition, seven patients whose samples were nonreactive in the RPR test and two patients whose samples were negative in the CAPITIA Syphilis-G test were diagnosed as having untreated syphilis. After discrepancies were reconciled, samples from five patients remained nonreactive in the RPR test and none remained negative in the CAPIFA Syphilis-G test. Final results indicate that the sensitivities of the RPR test and the CAPTIA Syphilis-G test are 86.1 and 100%o, respectively, and that the specificities are 99.4 and 99.9%o, respectively. In addition to the improved sensitivity and specificity of the CAPTIA Syphilis-G screen, other potential benefits of this assay lead us to believe that this method could serve as a better screening tool than the RPR test.

show abstract

mentioning

confidence: 99%

Evaluation of a Treponema pallidum enzyme immunoassay as a screening test for syphilis

Hooper

Malloy

Passen

1994

Clin Diagn Lab Immunol

View full text Add to dashboard Cite

show abstract

“…Treponemal test performance data during pregnancy are limited. In a single study that included 2,000 patients, manual treponemal test specificity using concordance among both tests as the reference standard (e.g., FTA-ABS or TPHA) was high for both tests (99.8% and 99.95%, respectively); however, for pregnant persons, this study did not have a control group (178). For manual treponemal immunoassays, one study of Captia EIA used TPPA as the reference standard and included 9,896 pregnant patients and 24,346 nonpregnant persons who were screened at an institution that screens high-prevalence populations, including persons living with HIV infection and men who have sex with men (MSM) (179).…”

Section: Serologic Test Performance In Pregnant Personsmentioning

confidence: 88%

CDC Laboratory Recommendations for Syphilis Testing, United States, 2024

Papp,

Park,

Fakile

et al. 2024

MMWR Recomm. Rep.

View full text Add to dashboard Cite

Summary This report provides new CDC recommendations for tests that can support a diagnosis of syphilis, including serologic testing and methods for the identification of the causative agent Treponema pallidum . These comprehensive recommendations are the first published by CDC on laboratory testing for syphilis, which has traditionally been based on serologic algorithms to detect a humoral immune response to T. pallidum . These tests can be divided into nontreponemal and treponemal tests depending on whether they detect antibodies that are broadly reactive to lipoidal antigens shared by both host and T. pallidum or antibodies specific to T. pallidum , respectively. Both types of tests must be used in conjunction to help distinguish between an untreated infection or a past infection that has been successfully treated. Newer serologic tests allow for laboratory automation but must be used in an algorithm, which also can involve older manual serologic tests. Direct detection of T. pallidum continues to evolve from microscopic examination of material from lesions for visualization of T. pallidum to molecular detection of the organism. Limited point-of-care tests for syphilis are available in the United States; increased availability of point-of-care tests that are sensitive and specific could facilitate expansion of screening programs and reduce the time from test result to treatment. These recommendations are intended for use by clinical laboratory directors, laboratory staff, clinicians, and disease control personnel who must choose among the multiple available testing methods, establish standard operating procedures for collecting and processing specimens, interpret test results for laboratory reporting, and counsel and treat patients. Future revisions to these recommendations will be based on new research or technologic advancements for syphilis clinical laboratory science.

show abstract

“…A positive Venereal Disease Research Laboratory combined with a positive fluorescent treponemal antibody absorption in a woman previously untreated for syphilis is considered by many authorities to be a sufficient indication for treatment. 167,168 In our practice, we sometimes run a battery of several treponemal and nontreponemal tests to maximize the chance of obtaining a true positive result. For asymptomatic women who test positive in early pregnancy, we test again 1 month later.…”

Section: Syphilismentioning

confidence: 99%

Clinical Focus: Infections in Pregnancy

Adler

Lambert

2014

Hospital Practice

View full text Add to dashboard Cite

Pregnant women are particularly susceptible to a number of infectious diseases, such as influenza, hepatitis E, malaria, and tuberculosis. The management of many other infections-including urinary tract infections, human immunodeficiency virus, and sexually transmitted diseases-is also made more complex by pregnancy; even if some infections do not pose a great risk to the expectant mother, they can impact fetal and neonatal development, thus posing a treatment challenge to physicians. By focusing on the most important diseases that physicians may encounter in pregnant patients, this review outlines the challenges associated with managing important infectious diseases in the pregnant population and references the most recent evidence and international treatment guidelines.

show abstract

Specificity of the FTA-ABS and TPHA tests during pregnancy.

Cited by 6 publications

References 15 publications

Evaluation of a Treponema pallidum enzyme immunoassay as a screening test for syphilis

Evaluation of a Treponema pallidum enzyme immunoassay as a screening test for syphilis

CDC Laboratory Recommendations for Syphilis Testing, United States, 2024

Clinical Focus: Infections in Pregnancy

Contact Info

Product

Resources

About